Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3
Overview
The aim of this study is to determine the role of human neutrophil peptide-1 to 3 in the occurrence of periprocedural myocardial infarction.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 2016
Interventions
- Other: Blood sample
- Blood sample drawn from participants for analysis of neutrophil peptide level
Clinical Trial Outcome Measures
Primary Measures
- Human Neutrophil Peptide Level
- Time Frame: Two hours
- Laboratory analysis and measurement of Human Neutrophil Peptide-1 to 3 levels
Participating in This Clinical Trial
Inclusion Criteria
- Troponin negative patients – Stable angina – Unstable angina – Positive screening tests Exclusion Criteria:
- Troponin positive – Technical failure of procedure – Hemodynamic unstability
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hillel Yaffe Medical Center
- Provider of Information About this Clinical Study
- Sponsor
- Overall Contact(s)
- Rami Abu Fanne, MD, PhD, 972-50-3573694, ramia@hadassah.org.il
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.